Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases;Empfehlungen für den einsatz von rituximab (anti-CD20-antikörper) bei bullösen autoimmundermatosen

JDDG - Journal of the German Society of Dermatology

Volumn 6, Issue 5, 2008, Pages 366-373

  Hertl, Michael ^a   Zillikens, Detlef ^b   Borradori, Luca ^c   Bruckner Tuderman, Leena ^d   Burckhard, Harald ^e   Eming, Rüdiger ^a   Engert, Andreas ^f   Goebeler, Matthias ^g   Hofmann, Silke ^d   Hunzelmann, Nicolas ^f   Karlhofer, Franz ^h   Kautz, Ocko ^d   Lippert, Undine ⁱ   Niedermeier, Andrea ^a   Nitschke, Martin ^b   Pfütze, Martin ^a   Reiser, Marcel ^f   Rose, Christian ^b   Schmidt, Enno ^j   Shimanovich, Iakov ^b   Sticherling, Michael ^k   Wolff Franke, Sonja ^a   more..

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b UNIVERSITY OF LÜBECK   (Germany)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d UNIVERSITY OF FREIBURG   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h Universitatsklinik fur Dermatologie   (Austria)

ⁱ UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^j UNIVERSITY OF WÜRZBURG   (Germany)

^k UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

more..

Author keywords

Autoantibody; B lymphocyte; Bullous skin diseases; Immune suppression; Rituximab

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; CLEMASTINE; COLCHICINE; CORTISONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACLIZUMAB; DAPSONE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ANGIONEUROTIC EDEMA; ARTICLE; AUTOIMMUNE SKIN DISEASE; BACTERIAL PNEUMONIA; BRONCHOSPASM; BULLOUS SKIN DISEASE; CHILL; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MECHANISM; DRUG USE; ENTEROPATHY; FEVER; HEADACHE; HUMAN; HYPOTENSION; IMMUNOGLOBULIN DEFICIENCY; LUNG EMBOLISM; MONOTHERAPY; NAUSEA; NONHODGKIN LYMPHOMA; PARANEOPLASTIC PEMPHIGUS; PNEUMOCYSTIS PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PYELONEPHRITIS; RHEUMATOID ARTHRITIS; SEPSIS; URTICARIA;

EID: 44049086991     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2007.06602.x     Document Type: Article

References (29)

1. 1 Arin MJ, Hunzelmann N. Anti‐B‐cell‐directed immunotherapy (rituximab) in the treatment of refractory pemphigus–an update. Eur J Dermatol 2005 ; 15: 224–230.
2. 2 McLaughlin P, Grillo‐Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence‐Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti‐CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of the patients respond to a four‐dose treatment program. J Clin Oncol 1998 ; 16: 2825–2833.
3. 3 Berinstein NL, Grillo‐Lopez AJ, White CA, Bence‐Bruckler I, Maloney D, Czuczman M, Green D, Rosenberg J, McLaughlin P, Shen D. Association of serum Rituximab (IDEC‐C2B8) concentration and anti‐tumor response in the treatment of recurrent low‐grade or follicular non‐Hodgkin's lymphoma. Ann Oncol 1998 ; 9: 995–1001.
4. 4 Reiser M, Wenger M, Nickenig C, Peter N, Metzner B, Pfreundschuh M. Serum levels and pharmacokinetic of ritu‐ximab in Bi‐weekly R‐CHOP in elderly patients with DLBCL treated in the RI‐COVER‐60 trial. J Clin Oncol 2006 ; 24: 7537A.
5. 5 Edwards JC, Szczepanski L, Szechinski J, Filipowicz‐Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B‐cell‐targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004 ; 350: 2572–2581.
6. 6 Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Repopulation of B lymphocytes in peripheral blood following B lymphocyte depletion with ritu‐ximab in rheumatoid arthritis. Arthritis Rheum 2006 ; 54: 613–620.
7. 7 Hertl M, Eming R, Borradori L. Rituximab (anti‐CD20 monoclonal antibody)–ultimate or first choice in pemphigus? Dermatology 2007 ; 214: 275–277.
8. 8 Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I. B‐cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose‐escalation trial of rituximab. Arthritis Rheum 2004 ; 50: 2580–2590.
9. 9 Edwards JCW, Cambridge G. B‐cell targeting in rheumatoid arthritis and other autoimmune diseases. Nature Rev Immunol 2006 ; 6: 394–403.
10. 10 Ahmed AR, Spigelman Z, Cavacini LA, Poster MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006 ; 355: 1772–1779.
11. 11 Joly P, Mouquet H, Roujeau JC, D'In‐can M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, Dou‐tre MS, Delaporte E, Pauwels C, Franck N, Caux F, Picard C, Tancrede‐Bohin E, Bernard P, Tron F, Hertl M, Musette P. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007 ; 357: 545–552.
12. 12 Borradori L, Lombardi T, Samson J, Gir‐ardet C, Saurat JH, Hugli A. Anti‐CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma‐associated paraneoplastic pemphigus. Arch Dermatol 2001 ; 137: 269–272.
13. 13 Arin MJ, Engert A, Krieg T, Hunzel‐mann N. Anti‐CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br. J. Dermatol, 2005 ; 153: 620–625.
14. 14 Schmidt E, Hunzelmann N, Zillikens D, Bröcker EB, Goebeler M. Rituxi‐mab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006 ; 31: 503–508.
15. 15 Eming R, Niedermeier A, Pfütze M, Jacobi A, Hertl M. Treating autoimmune bullous skin disorders with biologics. Boehncke WH, Radeke H (Eds.): Bio‐logics in General Medicine. Springer Science+Business Media, 2007.
16. 16 Kasperkiewicz M, Zillikens D. Rituxi‐mab (anti‐CD20) zur Behandlung von bullösen Autoimmundermatosen. Hautarzt 2007 ; 58: 115–121.
17. 17 Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with the anti‐CD20 monoclonal antibody (rituximab). Dermatology 2007 ; 214: 310–318.
18. 18 Niedermeier A, Worl P, Barth S, Schuler G, Hertl M. Delayed response of oral pemphigus vulgaris to rituximab treatment. Eur J Dermatol 2006 ; 16: 266–270.
19. 19 Goebeler M, Herzog S, Brocker EB, Zillikens D. Rapid response of treatment‐resistant pemphigus foliaceus to the anti‐CD20 antibody rituximab. Br J Dermatol 2003 ; 149: 899–901.
20. 20 Schmidt E, Herzog S, Bröcker EB, Zillikens D, Goebeler M. Rituximab induced long‐standing remission in a 14‐year‐old boy with treatment‐resistant pemphigus vulgaris. Br J Dermatol 2005 ; 153: 449–451.
21. 21 Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Serological changes following B cell depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003 ; 48: 2146–2154.
22. 22 Schmidt E, Benoit S, Bröcker E‐B, Zil‐likens D, Goebeler M. Successful treatment of recalcitrant epidermolysis bullosa acquisita with rituximab. Arch Dermatol 2006 ; 142: 47–50.
23. 23 Niedermeier A. Eming R, Pfütze M, Neumann CR, Happel C, Reich K, Hertl M. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti‐CD20 monoclonal antibodies). Arch Dermatol 2007 ; 143: 192–198.
24. 24 Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007 ; 156: 352–356.
25. 25 Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D. Treatment of severe pemphigus with protein A immunoad‐sorption, rituximab and intravenous im‐munoglobulins. Br J Dermatol 2007 ; doi: DOI: 10.1111/j.1365-2133.2007.08358.x.
26. 26 Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti‐CD20 monoclonal antibody (rituximab). Br J Dermatol 2003 ; 148: 602–603.
27. 27 Pfütze M, Eming R, Niedermeier A, U Kuhlmann, Hoyer J, Hertl M. Both immunoadsorption and rituximab induce prolonged clinical responses in pemphigus vulgaris. (einger. z. Publ.).
28. 28 Rituxan warning. FDA Consum. 2007 ; 41: 3.
29. 29 Pfütze M, Niedermeier A, Hertl M, Eming R. Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus. Eur J Dermatol. 2007 ; 17: 4–11.